Drugs / Veneclatra
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06447090 | Apr 2024 → May 2027 expected | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Veneclatra | “Veneclatra (VEN) 400 mg/d (reduced to 100 mg when combined with an azole), d1-7” NCT06447090 ↗ |
| Known as | VEN | “Veneclatra (VEN) 400 mg/d (reduced to 100 mg when combined with an azole), d1-7” NCT06447090 ↗ |